Post-earnings recap
Reported
Wed, Jul 29, 2026
EPS actual
$-0.21
EPS est.
$-0.24
EPS surprise
+12.86%
1-day move
-1.92%
Teladoc Health reported an EPS loss of $-0.21, which was better than expected, but revenue details were not disclosed. The stock reacted negatively, dropping 1.92%. Investors may be concerned about the lack of revenue information and guidance, which could impact future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +12.86% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results. Therefore, management's messaging is unclear.
Teladoc Health, Inc. is a leader in telehealth services, providing virtual healthcare solutions to patients. As part of the Health Care Technology sector, it plays a crucial role in expanding access to medical services, especially as demand for remote healthcare continues to grow.
Last quarter
In Q1-2026, Teladoc reported an EPS of -$0.36, which was worse than the expected -$0.32. The stock reacted negatively, dropping 0.83% the following day.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
-2.59%
Avg 1-day reaction
-1.79%
Overall, expectations are mixed as Teladoc has struggled to meet earnings estimates in recent quarters. Investors are looking for signs of improvement in both patient engagement and revenue.
Bull case
If Teladoc can demonstrate a significant increase in patient visits and revenue growth, it could signal a turnaround, boosting investor confidence.
Bear case
Continued losses and failure to meet expectations could lead to further declines in stock price, especially given the company's recent performance history.
The print will turn on these.
Q1
What is the expected number of patient visits this quarter?
A significant increase in patient visits could indicate a recovery in demand and positively impact revenue.
Q2
Will Teladoc provide any guidance on future revenue growth?
Guidance on revenue growth will be critical for investor sentiment, especially after recent disappointing results.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The Street may be underestimating the potential for a rebound in patient visits, which could lead to better-than-expected revenue.
Supporting evidence
Recent trends suggest a growing acceptance of telehealth services, which could drive increased patient engagement.
The options market is pricing a move of 32.79%, indicating that traders expect significant volatility, which may not align with the consensus view.
Key risk
If patient visits exceed expectations, it could invalidate the current bearish sentiment.
Pre-commit to what would confirm each case.
The core thesis revolves around whether Teladoc can turn around its recent performance and regain investor confidence.
Bull confirmed if
A positive EPS surprise of at least $0.05 would confirm the bull case.
Bear confirmed if
An EPS loss greater than -$0.40 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±32.79%
Historical Avg
±2.4%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.
Options are pricing ±32.8% while TDOC has averaged ±2.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
57.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3,702.72
655 sh
1 insider
Net
$3,702.72
Net selling
Most Active Insiders· 1 open-market trade
$3,702.72
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
86.83%
of float
Insider
0.74%
of float
Holders
468
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
16,223,134 sh · $90.2M
8.93%
11.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Teladoc beats expectations and raises guidance, history suggests the stock could rise by around 2.54% on the first trading day.
In line / cautious
If results are in line with expectations but management is cautious, the stock may see a muted reaction, reflecting uncertainty.
Miss
If Teladoc misses expectations, history suggests a potential decline of about 1.82% on the first trading day.
The lines on the call that would change the story.
Recent Transactions
Oct 2, 2026 · @ $5.65
655 sh
$3,702.72
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Portfolio Management LLC
12,685,592 sh · $70.5M
6.98%
3.2%
Point72 Asset Management, L.P.
8,239,927 sh · $45.8M
4.54%
6.7%
Renaissance Technologies, LLC
8,072,842 sh · $44.9M
4.44%
-0.2%
Voss Capital, LP
8,046,679 sh · $44.7M
4.43%
91.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.